中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2013年
3期
157-160
,共4页
黄伍奎%樊喜文%杨树法%由丽娜%帕哈尔丁白克热%刘墨%顾朋%王萍菊
黃伍奎%樊喜文%楊樹法%由麗娜%帕哈爾丁白剋熱%劉墨%顧朋%王萍菊
황오규%번희문%양수법%유려나%파합이정백극열%류묵%고붕%왕평국
金龙胶囊%肝癌%TACE%不良反应
金龍膠囊%肝癌%TACE%不良反應
금룡효낭%간암%TACE%불량반응
Jinlong capsule%heptocellular carcinoma%transcatheter arterial chemoembolization%adverse reaction
目的:探讨金龙胶囊减少原发性肝癌患者行肝动脉插管灌注化疗栓塞术后不良反应的作用.方法:82例原发性肝癌患者按随机原则分为对照组和试验组.在肝动脉插管灌注化疗栓塞术后第1日,试验组患者开始口服金龙胶囊,对照组不服用,其余治疗措施相同.结果:试验组患者红细胞和血小板下降的例数较少(P<0.05),两组总胆红素差异无统计学意义(P>0.05),谷丙转氨酶、白蛋白、钾、钠与对照组比较差异有统计学意义(P<0.05),试验组患者术后5 d的食欲、精神、睡眠、疲乏评分情况优于对照组,腹痛、腹胀持续时间较短(P<0.05).结论:金龙胶囊能减少TACE患者术后部分不良反应的发生,缩短不良反应持续的时间,能提高TACE患者术后近期生活质量,减少TACE对患者机体的损伤.
目的:探討金龍膠囊減少原髮性肝癌患者行肝動脈插管灌註化療栓塞術後不良反應的作用.方法:82例原髮性肝癌患者按隨機原則分為對照組和試驗組.在肝動脈插管灌註化療栓塞術後第1日,試驗組患者開始口服金龍膠囊,對照組不服用,其餘治療措施相同.結果:試驗組患者紅細胞和血小闆下降的例數較少(P<0.05),兩組總膽紅素差異無統計學意義(P>0.05),穀丙轉氨酶、白蛋白、鉀、鈉與對照組比較差異有統計學意義(P<0.05),試驗組患者術後5 d的食欲、精神、睡眠、疲乏評分情況優于對照組,腹痛、腹脹持續時間較短(P<0.05).結論:金龍膠囊能減少TACE患者術後部分不良反應的髮生,縮短不良反應持續的時間,能提高TACE患者術後近期生活質量,減少TACE對患者機體的損傷.
목적:탐토금룡효낭감소원발성간암환자행간동맥삽관관주화료전새술후불량반응적작용.방법:82례원발성간암환자안수궤원칙분위대조조화시험조.재간동맥삽관관주화료전새술후제1일,시험조환자개시구복금룡효낭,대조조불복용,기여치료조시상동.결과:시험조환자홍세포화혈소판하강적례수교소(P<0.05),량조총담홍소차이무통계학의의(P>0.05),곡병전안매、백단백、갑、납여대조조비교차이유통계학의의(P<0.05),시험조환자술후5 d적식욕、정신、수면、피핍평분정황우우대조조,복통、복창지속시간교단(P<0.05).결론:금룡효낭능감소TACE환자술후부분불량반응적발생,축단불량반응지속적시간,능제고TACE환자술후근기생활질량,감소TACE대환자궤체적손상.
Objective: This study aims to discuss the effect of Jinlong capsule on decreasing adverse reaction after transcatheter arterial chemoembolization(TACE)for patients with heptocellular carcinoma. Methods: We divided 82 patients with heptocellular carcinoma into the contrast group and experiment group using random principle. On the first day after TACE, the experiment group started to take Jinlong capsule orally, whereas the contrast group did not; other treatment methods were the same. Results: The decreased cases of the red blood cell and thrombocyte in the experiment group were lower than those in the contrast group (P<0.05); the variance of the total bilirubin had no statistical significance between the two groups (P>0.05), whereas statistical significance was observed on the variance of Alanine transaminase, albumin, potassium, and sodium in the blood between two groups (P<0.05). Five days after TACE, the score of appetite, energy, sleep, and fatigue for the experiment group were superior to the contrast group; the persistence of stomachache and abdominal distension in the experiment group were shorter than that in the contrast group (P<0.05). Conclusion: Jinlong capsule can decrease the incidence of partial adverse reaction after TACE, cut short the persisting time of adverse reaction, improves the quality of life after TACE, and reduces damage to organs caused by TACE.